A more skeptical take. http://blogs.sciencemag.org/pipeline/archives/2017/01/11/121...
Tl;dr Alzheimer's is hard to drug, and the approach this company is trying has been tried before.
Tl;dr Alzheimer's is hard to drug, and the approach this company is trying has been tried before.
The plan is simple. You fund a company and spend $5mn acquiring the rights to a drug that might be worth billions (not very likely, if you can get it at that price). And before investing your own money to find out, you sell one fourth of that company for $360mn because "Hey, it could be worth billions!!!!"
This sounds like a pump and dump or money extraction scheme. I imagine it was mostly sold to pensions, etc.